Prof. Tay Sun Kuie
Senior Consultant Obstetrician and Gynecologist
Singapore General Hospital
Optimizing triage of HPV positive patients with p16/Ki67 dual stain biomarkers: Singapore experience
Thursday, 16th May 2024
13:00 - 14:00 (GMT +8)
View other Time Zones
The goal of cervical cancer screening is to detect precancerous lesions, which if left untreated, can develop into cervical cancer. While Pap cytology has had a positive impact on HPV and cervical cancer screening over the past 50 years, it is resource-intensive and subject to misinterpretation and missed disease.
By harnessing p16-Ki67 dual-biomarker immunocytochemistry, FDA-approved CINtec® PLUS Cytology serves as an objective indicator of transforming HPV infections in patients with abnormal Pap cytology and/or HPV-positive screening results.
In this webinar, our experts unveil how p16-Ki67 dual biomarker testing optimizes triage processes and allows lab professionals to help clinicians be more certain in selecting women who may benefit most from colposcopy and in follow up recommendations.
Join us in this session, as they share their experience with CINtec® PLUS biomarker testing, as a triage tool in managing patients with abnormal Pap and/or HPV-positive results.
Who should attend:
- Gynecologists / Gyne-oncologists, Pathologists, Laboratory staff / lab scientists, Cytotechnologists, General practitioners, Health practitioners involved in women’s health, Residents/trainees or any professionals interested in understanding molecular diagnostics relevant to cervical cancer screening.
Key reasons to attend:
- Learn about the latest advancements in cervical cancer screening with FDA-approved CINtec® PLUS Cytology, harnessing dual-biomarker p16-Ki67 immunocytochemistry, to enhance accuracy in detecting transforming HPV infections.
- Discover how p16/Ki67 dual stain biomarker testing streamlines triage processes for HPV positive or abnormal Pap cytology results, enabling confident follow-up recommendations and improved patient outcomes.
- Gain insights into how p16/Ki67 dual stain biomarker testing enables clinicians optimize cervical disease management workflow and resource allocation.
Faculty
Speaker |
|
SpeakerProf. Tay Sun KuieSenior Consultant Obstetrician and Gynecologist |
MBBS, FRCOG (UK), MD (Lond), FAMS, MAppLaw
Professor Tay is a senior consultant Obstetrician and Gynecologist, with special interests in gynaecological tumours, colposcopy and management of cervical screening abnormalities, and endometriosis.
Professor Tay graduated MBBS and MD from University College London, completed his specialist training in obstetrics & gynaecology in London with subspecialty training in colposcopy and laser treatment of pre-invasive cervical disease. He had fellowship training in immunotherapy of gynaecological cancer at the MD Anderson Medical Centre and Institute of Tumours, Houston, Texas, USA in 1993. Professor Tay has been a fellow of the Academy of Medicine, Singapore (FAMS) and the Royal College of Obstetricians and Gynaecologists London (FRCOG) in 1989 and 1998, respectively. He was Clinical Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore in 2000 and, later, Clinical Professor, at Duke-NUS Medical School. Prof Tay is faculty member in the academic clinical program for residency training, a medical educator and author of three books and many text books in gynaecology, has more than 110 publications in peer reviewed medical and scientific journals, and is a frequent speaker in regional and international conferences.
Speaker |
Dr. Sangeeta MantooSenior Consultant, Anatomical Pathology |
|
SpeakerDr. Sangeeta MantooSenior Consultant, Anatomical Pathology |
Dr Mantoo Sangeeta
FRCPath(UK) , MD (Pathology) , MBBS
Dr Sangeeta Mantoo is Senior Consultant and Head of Cytology section in the Department of Anatomical Pathology, Singapore General Hospital. After completing her Masters in Pathology in India, she became member and fellow of the UK Royal College of Pathologists. She was awarded observership at University Hospital, Nantes, France in 2012 and Fellowship in Cytopathology and Molecular Cytopathology at Cleveland Clinic, Ohio, USA in 2016. Dr Mantoo is Clinical Assistant Professor, Duke-NUS Graduate Medical School, Core Faculty of SingHealth Pathology Residency Program, and lecturer at Nanyang Technological University, and has received Outstanding Faculty Awards and Inspiring Mentor Awards several times. She is Honorary Secretary of the Society of Cytology, Singapore, Council Member of Singapore Society of Pathologists and has been International member of European Congress of Pathology and American Society of Cytopathology. Dr Mantoo is involved in several funded institutional and inter-institutional research projects, with numerous conference/seminar presentations & peer-reviewed journal publications.
Moderator |
Dr. Richie LazaroRegional Pathologist APAC
|
|
Dr. Richie LazaroRegional Pathologist APAC, |
Ana Richelia (“Richie”) Jara-Lazaro, MD, FPSP, DAMS, DipRCPath
Dr. Richie Lazaro joined Roche in 2019, in the non-commercial division of Medical and Scientific Affairs – Pathology, at Roche Diagnostics Asia Pacific, based in Singapore.
She earned her Medical Degree in University of the East (UERMMMC) in Philippines, is a Fellow of the Philippine Society of Pathologists, and Diplomate of the Singapore Academy of Medicine and UK Royal College of Pathologists.
Previously Associate Pathology Director in a leading global clinical trials organisation, Q2 Solutions, Dr. Jara-Lazaro headed histopathology and served as Principal Investigator for global companion diagnostics and oncology clinical trials. Prior to this role, Dr. Jara-Lazaro worked in Singapore General Hospital Pathology Department, where she also subspecialized in breast and urologic pathology, and was clinical lead of the digital pathology pilot project in collaboration with the Singapore Ministry of Health.
She has multiple peer-reviewed international publications, is a manuscript reviewer for several pathology journals, and regularly participates in regional and international conferences.
Advancing Triage for HPV positive Women: Guideline Updates & Insights from USA and China
Tuesday, 6th August 2024
13:00 - 14:00 (GMT +8)
View other Time Zones
The goal of cervical cancer screening is to detect precancerous lesions, which if left untreated, can develop into cervical cancer. While Pap cytology has had a positive impact on HPV and cervical cancer screening over the past 50 years, it is resource-intensive and subject to misinterpretation and missed disease.
By harnessing p16-Ki67 dual-biomarker immunocytochemistry, FDA-approved CINtec® PLUS Cytology serves as an objective indicator of transforming HPV infections in patients with abnormal Pap cytology and/or HPV-positive screening results.
In this webinar, our experts will share the latest guideline updates which recommend the use of p16/Ki-67 dual staining biomarkers in primary and co-testing screening algorithms. Dr. Leigh A. Cantrell and Dr. Xu Jingjing will also unveil how dual staining cytology optimises triage processes in their routine practices. Discover how this advancement enables lab professionals to assist clinicians in confidently selecting women who may benefit most from colposcopy and follow-up recommendations
Join us in this session, as they share their experience with CINtec® PLUS biomarker testing, as a triage tool in managing patients with abnormal Pap and/or HPV-positive.
Who should attend:
- Gynecologists/Gyne-oncologists, Pathologists, Laboratory staff/lab scientists, Cytotechnologists, General practitioners, Health practitioners involved in women’s health, Residents/trainees or any professionals interested in understanding molecular diagnostics relevant to cervical cancer screening.
Key reasons to attend:
- Stay informed about how ASCCP and WHO have updated cervical cancer screening guidelines to include the use of dual staining in triage of HPV positive individuals.
- Learn about the latest advancements in cervical cancer screening with FDA-approved CINtec® PLUS Cytology, harnessing dual-biomarker p16-Ki67 immunocytochemistry, to enhance accuracy in detecting transforming HPV infections.
- Discover how p16/Ki67 dual stain biomarker testing streamlines triage processes for HPV positive or abnormal Pap cytology results, enabling confident follow-up recommendations and improved patient outcomes.
- Gain insights into how p16/Ki67 dual stain biomarker testing enables clinicians to optimize cervical disease management workflow and resource allocation.
Faculty
Speaker |
Dr. Leigh A. CantrellGynecologic Oncologist |
|
SpeakerDr. Leigh A. CantrellGynecologic Oncologist |
Dr. Leigh A Cantrell, MD, MSPH
Dr. Leigh Cantrell treats women with gynecologic malignancies, including both surgical treatments and chemotherapy. She is an associate professor in the Division of Gynecologic Oncology and serves as the Obstetrics and Gynecology Residency Program Director. She is board-certified in obstetrics and gynecology and gynecologic oncology.
Dr. Cantrell completed her undergraduate studies, medical degree, Master of Science in Public Health, residency in obstetrics and gynecology and fellowship in gynecologic oncology at the University of North Carolina at Chapel Hill. Her fellowship training included extensive training in robotic surgery and her robotic surgery skills were of special interest when she was recruited to join the faculty at UVA in 2010. She serves as chair of the Robotic Surgeon's Group at University Hospital.
As a gynecologic oncologist, the nature of the treatment plans Dr. Cantrell develops for her patients often create a long-lasting patient-physician bond — an element of her role that she finds deeply fulfilling.
Speaker |
Dr. Xu JingjingPathologist |
|
SpeakerDr. Xu JingjingPathologist |
____________________________________________
Moderator |
Dr. Richie LazaroRegional Pathologist APAC
|
|
Dr. Richie LazaroRegional Pathologist APAC, |
Ana Richelia (“Richie”) Jara-Lazaro, MD, FPSP, DAMS, DipRCPath
Dr. Richie Lazaro joined Roche in 2019, in the non-commercial division of Medical and Scientific Affairs – Pathology, at Roche Diagnostics Asia Pacific, based in Singapore.
She earned her Medical Degree in University of the East (UERMMMC) in Philippines, is a Fellow of the Philippine Society of Pathologists, and Diplomate of the Singapore Academy of Medicine and UK Royal College of Pathologists.
Previously Associate Pathology Director in a leading global clinical trials organisation, Q2 Solutions, Dr. Jara-Lazaro headed histopathology and served as Principal Investigator for global companion diagnostics and oncology clinical trials. Prior to this role, Dr. Jara-Lazaro worked in Singapore General Hospital Pathology Department, where she also subspecialized in breast and urologic pathology, and was clinical lead of the digital pathology pilot project in collaboration with the Singapore Ministry of Health.
She has multiple peer-reviewed international publications, is a manuscript reviewer for several pathology journals, and regularly participates in regional and international conferences.
Live Webinar Date & Time
 |
Date:6th August 2024 at 13:00-14:00 (GMT+8) |
 |
|